Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report)’s share price shot up 1.7% during trading on Friday . The company traded as high as $1.23 and last traded at $1.19. 201,385 shares were traded during trading, a decline of 43% from the average session volume of 354,820 shares. The stock had previously closed at $1.17.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Iterum Therapeutics in a research report on Friday, June 21st.
Read Our Latest Report on ITRM
Iterum Therapeutics Stock Performance
Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) last released its earnings results on Monday, May 13th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.11. Equities research analysts forecast that Iterum Therapeutics plc will post -1.76 earnings per share for the current fiscal year.
About Iterum Therapeutics
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Further Reading
- Five stocks we like better than Iterum Therapeutics
- What Investors Need to Know to Beat the Market
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.